This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

An Advanced Echocardiographic Evaluation of Nebivolol

This study has been terminated.
(Slow enrollment)
Forest Laboratories
Information provided by (Responsible Party):
Jack Rubinstein, University of Cincinnati Identifier:
First received: April 2, 2010
Last updated: October 22, 2015
Last verified: October 2015
The purpose of this study is to determine if Nebivolol has any effect on heart function determined by changes in echocardiographic data or exercise tolerance.

Condition Intervention Phase
Hypertension Drug: nebivolol Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Advanced Echocardiographic Evaluation of Nebivolol

Resource links provided by NLM:

Further study details as provided by Jack Rubinstein, University of Cincinnati:

Primary Outcome Measures:
  • Change in Systolic and Diastolic Myocardial Function [ Time Frame: Baseline to day 180 ]
    Cannot report as only 1 patient was evaluated and data will not be able to remain anonymous.

Secondary Outcome Measures:
  • Exercise Tolerance [ Time Frame: Baseline to day 180. ]
    Changes in exercise tolerance and time from baseline to 180 days.

Enrollment: 2
Study Start Date: September 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nebivolol 5 or 10 mg, oral, daily
Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
Drug: nebivolol
nebivolol 5 or 10 mg oral, daily
Other Name: Bystolic

Detailed Description:
Subjects will be given either 5 or 10 mg daily of oral Nebivolol for blood pressure control. They will undergo stress echocardiography at baseline, day 14, 90 and 180.

Ages Eligible for Study:   20 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of hypertension
  2. Written informed consent before initiation of any study related procedure
  3. Baseline Blood pressure > 140 systolic or >90 diastolic if on no antihypertensive therapy.
  4. Currently taking one antihypertensive or one antihypertensive and one diuretic for the treatment of hypertension.

Exclusion Criteria:

  1. Physical limitations resulting in a limited ability to walk on treadmill for stress echo
  2. Intolerance to beta blockers
  3. On more than one medication for the treatment of hypertension unless the second medication is a diuretic.
  4. Currently pregnant or breast feeding.
  5. LFT > 3 X ULN
  6. HgA1C > 7
  7. Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within past 30 days of enrollment
  8. Unwilling to follow protocol or return for study related procedures.
  9. Any of the following conditions:

    Coronary artery disease Heart failure Valvular heart disease Ischemic heart disease Atrial fibrillation Pacemaker ICD Hyperlipidemia Diabetes Mellitus Stroke/TIA Anemia COPD Asthma Renal failure requiring dialysis Liver failure Cirrhosis Thyroid dysfunction

  10. Any other medical condition that in the PI's opinion could affect myocardial function.
  11. Current ETOH or illicit drug abuse -
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01206439

United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
Sponsors and Collaborators
Jack Rubinstein
Forest Laboratories
Principal Investigator: Jack Rubinstein, MD University of Cincinnati
  More Information

Responsible Party: Jack Rubinstein, Assistant Professor, University of Cincinnati Identifier: NCT01206439     History of Changes
Other Study ID Numbers: UC- 09-12-31-04
Study First Received: April 2, 2010
Results First Received: August 24, 2015
Last Updated: October 22, 2015

Additional relevant MeSH terms:
Antihypertensive Agents
Vasodilator Agents
Adrenergic beta-1 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on August 18, 2017